{ "FullStudy":{ "Rank":218201, "Study":{ "ProtocolSection":{ "IdentificationModule":{ "NCTId":"NCT01511419", "OrgStudyIdInfo":{ "OrgStudyId":"LAIV-H7N3-01" }, "Organization":{ "OrgFullName":"PATH", "OrgClass":"OTHER" }, "BriefTitle":"Safety Trial of Live Attenuated Influenza (H7N3) Vaccine", "OfficialTitle":"Reactogenicity, Safety and Immunogenicity of a Live Monovalent A/17/Mallard/Netherlands/00/95 (H7N3) Influenza Vaccine" }, "StatusModule":{ "StatusVerifiedDate":"January 2019", "OverallStatus":"Completed", "ExpandedAccessInfo":{ "HasExpandedAccess":"No" }, "StartDateStruct":{ "StartDate":"April 2012" }, "PrimaryCompletionDateStruct":{ "PrimaryCompletionDate":"June 2012", "PrimaryCompletionDateType":"Actual" }, "CompletionDateStruct":{ "CompletionDate":"July 2012", "CompletionDateType":"Actual" }, "StudyFirstSubmitDate":"January 5, 2012", "StudyFirstSubmitQCDate":"January 12, 2012", "StudyFirstPostDateStruct":{ "StudyFirstPostDate":"January 18, 2012", "StudyFirstPostDateType":"Estimate" }, "ResultsFirstSubmitDate":"July 16, 2018", "ResultsFirstSubmitQCDate":"January 22, 2019", "ResultsFirstPostDateStruct":{ "ResultsFirstPostDate":"April 22, 2019", "ResultsFirstPostDateType":"Actual" }, "LastUpdateSubmitDate":"January 22, 2019", "LastUpdatePostDateStruct":{ "LastUpdatePostDate":"April 22, 2019", "LastUpdatePostDateType":"Actual" } }, "SponsorCollaboratorsModule":{ "ResponsibleParty":{ "ResponsiblePartyType":"Sponsor" }, "LeadSponsor":{ "LeadSponsorName":"PATH", "LeadSponsorClass":"OTHER" }, "CollaboratorList":{ "Collaborator":[ { "CollaboratorName":"Ministry of Health, Russian Federation", "CollaboratorClass":"OTHER_GOV" },{ "CollaboratorName":"Research Institute of Influenza, Russia", "CollaboratorClass":"OTHER" },{ "CollaboratorName":"Institute of Experimental Medicine, Russia", "CollaboratorClass":"OTHER" } ] } }, "OversightModule":{ "OversightHasDMC":"Yes" }, "DescriptionModule":{ "BriefSummary":"The study hypothesis is that two doses of cold-adapted, live monovalent A/17/mallard/Netherlands/00/95 (H7N3) influenza vaccine will be safe and immunogenic in healthy adults.", "DetailedDescription":"This is a phase I, double-blind, individually-randomized (3:1, vaccine:placebo), controlled trial with two groups, LAIV H7N3 and matched placebo. Healthy male and female adults 18 through 49 years of age will be invited to participate. For feasibility reasons and in order for an independent Safety Monitoring Committee (SMC) to review safety data in a small group of subjects initially, the total cohort of 40 subjects will be enrolled in two sub-cohorts: one cohort of 12 subjects, randomized at 3:1 (9 vaccine and 3 placebo), followed two weeks later by a second cohort of 28 subjects randomized at 3:1 (21 vaccine and 7 placebo). After all 12 volunteers of the first sub-cohort have been observed for the first isolation period (Day 1 to Day 7), an interim safety review will be performed by the SMC. The SMC will review all adverse events (AEs), including clinical laboratory evaluations (pre- and post-vaccination) and shedding data, for all subjects and will advise if the volunteers of the first sub-cohort may receive dose two of study vaccine or placebo and if the additional 28 volunteers of the second sub-cohort may be enrolled into the study. As for the first sub-cohort, the SMC will also review all safety data for the second sub-cohort and for the entire participant population of the trial. For each sub-cohort, the procedures and timelines are here summarized.\n\nOn the day of first screening, about 7 days (between 4 and 14 days) prior to administration of dose one of study vaccine or placebo, subjects will be screened for eligibility through medical history review, physical examination, testing for serologic evidence of chronic viral infection [human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV), with proper pre- and post-test counseling], routine biochemical and hematological blood tests and urinalysis by dipstick.\n\nSubject screening for eligibility will continue and be completed on the second screening day (S2). This second screening day will occur the same day as scheduled admission to the isolation unit and administration of study vaccine or placebo (Day 0). Women will undergo pregnancy tests using urine samples. All subjects will undergo an ear, nose and throat (ENT) examination. Fully eligible subjects will be admitted to the isolation unit. At that time, nasal swab, nasal wick, and blood specimens will be collected for virologic and immunological testing prior to administration of study vaccine or placebo. Blood and urine specimens will be again collected for routine biochemical and hematological blood tests and urinalysis by dipstick; these results will serve to define baseline status for subject prior to receipt of study vaccine or placebo but will not be used for screening purposes. Subjects will be unaware of which allocation, LAIV H7N3 or matched placebo, is received; study vaccine and placebo will be masked. Subjects will be carefully monitored for adverse reactions while in the isolation unit.\n\nAll subjects will remain in the isolation unit for at least 7 days after receipt of study vaccine or placebo. Nasal swabs will be collected daily while subjects are in isolation to test for presence of influenza virus shed in the nasal passage. Any subject exhibiting conjunctivitis will also have a conjunctival swab collected on the day of appearance of the sign. Any subject exhibiting influenza A virus shedding, as determined by real-time reverse transcriptase polymerase chain reaction (RT-PCR) positivity on a nasal swab specimen, in the 2 days prior to each planned discharge day after each dose (Days 6 or 7 or Days 34 or 35) will be kept in the isolation until PCR-diagnosis results confirm that no influenza virus is present in a tested clinical specimen for at least two consecutive days. Any subject still exhibiting evidence of influenza virus shedding in a nasal swab on Days 6 or 7 or Days 34 or 35 post-administration with each dose might be placed on influenza antiviral (oseltamivir) treatment at the standard dose for treatment of 75 milligrams (mg) twice a day for a course of 5 days.\n\nAfter discharge from the isolation unit, subjects will complete diary cards for AEs and use of concomitant medications. Subjects will return to the isolation unit at four weeks (Day 28) after administration of dose one of study vaccine or placebo. At that time, similar procedures will be used for admittance to the isolation unit, for receipt of dose two of study vaccine or placebo and for isolation and follow-up, with the additional procedure of review of interim histories (and diary cards) since first discharge after dose one.\n\nAfter second discharge from the isolation unit, subjects will again complete diary cards for AEs and use of concomitant medications. Subjects will then return to the study center at four weeks (Day 56) after administration of dose two of study vaccine or placebo for their final study visit. Interim histories (and diary cards) will again be reviewed and final blood and nasal wick specimens will be collected. Women will also undergo a final pregnancy screen. Subjects will complete the study at this time.\n\nFor assessment of safety, subjects will be observed for two hours after each administration of study vaccine or placebo. Twice daily (early morning and late afternoon) examination will be also used to assess reactions for 7 days after each administration of study vaccine or placebo. ENT examination will also occur once per day on Days 7, 28, 35 and 56. Subjects will complete diary cards for unsolicited AEs from the day of each discharge until return to the isolation unit for dose two (at Day 28) or until return to the study center for the final study visit at four weeks post dose two (at Day 56). To assess safety, blood and urine specimens will also be collected on days 7, 28 (prior to administration of dose two of study vaccine or placebo), 35 and 56, for testing by routine biochemical and hematological blood tests and by urinalysis by dipstick.\n\nFor the evaluation of mucosal immunoglobulin A (IgA) antibody, nasal wick specimens will be collected on Day 0 (prior to administration of dose one of study vaccine or placebo), on Day 28 (prior to administration of dose two of study vaccine or placebo) and on Day 56. For the evaluation of serum antibodies (by hemagglutination inhibition [HAI], microneutralization and IgA and immunoglobulin G [IgG] EIA), serum specimens will be collected on Day 0 (prior to administration of dose one of study vaccine or placebo), on Day 28 (prior to administration of dose two of study vaccine or placebo) and on Day 56. To study virus infectivity (by isolation in chicken embryos) and stability (by molecular sequencing of any isolated virus), nasal swab specimens will be taken on Days 1, 2, 3, 5, 7, 29, and 31. To assess priming and stimulation of cytotoxic T lymphocytes and other cytokine indicators, whole blood for isolation of peripheral blood mononuclear cells (PBMCs) will be collected on Days 0 (prior to administration of dose one of study vaccine or placebo), on Day 28 (prior to administration of dose two of study vaccine or placebo) and on Day 56." }, "ConditionsModule":{ "ConditionList":{ "Condition":[ "Influenza", "Avian Influenza" ] }, "KeywordList":{ "Keyword":[ "Influenza", "Vaccine", "Pandemic", "H7N3" ] } }, "DesignModule":{ "StudyType":"Interventional", "PhaseList":{ "Phase":[ "Phase 1" ] }, "DesignInfo":{ "DesignAllocation":"Randomized", "DesignInterventionModel":"Parallel Assignment", "DesignPrimaryPurpose":"Prevention", "DesignMaskingInfo":{ "DesignMasking":"Quadruple", "DesignWhoMaskedList":{ "DesignWhoMasked":[ "Participant", "Care Provider", "Investigator", "Outcomes Assessor" ] } } }, "EnrollmentInfo":{ "EnrollmentCount":"40", "EnrollmentType":"Actual" } }, "ArmsInterventionsModule":{ "ArmGroupList":{ "ArmGroup":[ { "ArmGroupLabel":"LAIV H7N3", "ArmGroupType":"Experimental", "ArmGroupDescription":"Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.\n\nName of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.\n\nDose: ≥7.5 log egg infectious dose (EID) 50/0.5 ml dose; 0.25 ml/nare.\n\nRoute of administration: Intranasal aerosol.\n\nDuration of treatment: Two doses were delivered, one on Day 0 and one on Day 28.", "ArmGroupInterventionList":{ "ArmGroupInterventionName":[ "Biological: LAIV H7N3" ] } },{ "ArmGroupLabel":"Placebo", "ArmGroupType":"Placebo Comparator", "ArmGroupDescription":"Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.\n\nDose: 0.5 ml; 0.25 ml/nare\n\nRoute of administration: Intranasal aerosol\n\nDuration of treatment: Two doses were delivered, one on Day 0 and one on Day 28", "ArmGroupInterventionList":{ "ArmGroupInterventionName":[ "Biological: placebo" ] } } ] }, "InterventionList":{ "Intervention":[ { "InterventionType":"Biological", "InterventionName":"LAIV H7N3", "InterventionDescription":"2 doses of vaccine", "InterventionArmGroupLabelList":{ "InterventionArmGroupLabel":[ "LAIV H7N3" ] }, "InterventionOtherNameList":{ "InterventionOtherName":[ "A/17/mallard/Netherlands/00/95 (H7N3)" ] } },{ "InterventionType":"Biological", "InterventionName":"placebo", "InterventionDescription":"2 doses of placebo", "InterventionArmGroupLabelList":{ "InterventionArmGroupLabel":[ "Placebo" ] } } ] } }, "OutcomesModule":{ "PrimaryOutcomeList":{ "PrimaryOutcome":[ { "PrimaryOutcomeMeasure":"Number of Participants With Immediate Reactions", "PrimaryOutcomeDescription":"From administration of any dose, immediate reaction measured as observed by study staff or reported by the subject to study staff in case of an anaphylactic reaction.", "PrimaryOutcomeTimeFrame":"2 hours post-administration on Days 0 and 28" },{ "PrimaryOutcomeMeasure":"Adverse Events Associated With Intranasal Vaccination", "PrimaryOutcomeDescription":"From solicited local and systemic reactions", "PrimaryOutcomeTimeFrame":"Greater than 2 hours through 7 days following any dose" },{ "PrimaryOutcomeMeasure":"All Other Adverse Events", "PrimaryOutcomeDescription":"Including unsolicited events and abnormal laboratory findings", "PrimaryOutcomeTimeFrame":"7 days following any dose" },{ "PrimaryOutcomeMeasure":"Participants With Serious Adverse Events (SAEs)", "PrimaryOutcomeDescription":"Including abnormal laboratory findings", "PrimaryOutcomeTimeFrame":"Within 4 weeks of receipt of any dose" } ] }, "SecondaryOutcomeList":{ "SecondaryOutcome":[ { "SecondaryOutcomeMeasure":"Number/Percentage of Subjects With Seroconversion for Serum Hemagglutination Inhibition (HAI)", "SecondaryOutcomeDescription":"Seroconversion was defined as at least a four-fold rise after each dose from baseline or as the mean titer after each dose", "SecondaryOutcomeTimeFrame":"28 days (Dose 1) and 56 days (Dose 2)" },{ "SecondaryOutcomeMeasure":"Number/Percentage of Subjects With Serum Neutralizing Antibodies", "SecondaryOutcomeDescription":"Measured using microneutralization assay. Seroconversion was defined as at least a four-fold rise after each dose from baseline or as the mean titer after each dose", "SecondaryOutcomeTimeFrame":"28 days (Dose 1) and 56 days (Dose 2)" },{ "SecondaryOutcomeMeasure":"Number/Percentage of Subjects With Seroconversion for Serum Immunoglobulin A (IgA)", "SecondaryOutcomeDescription":"Measured by enzyme-linked immunoassay (EIA). Seroconversion was defined as at least a four-fold rise after each dose from baseline or as the mean titer after each dose", "SecondaryOutcomeTimeFrame":"28 days (Dose 1) and 56 days (Dose 2)" },{ "SecondaryOutcomeMeasure":"Number/Percentage of Subjects With Seroconversion for Serum Immunoglobulin G (IgG)", "SecondaryOutcomeDescription":"Measured by enzyme-linked immunoassay (EIA). Seroconversion was defined as at least a four-fold rise after each dose from baseline or as the mean titer after each dose", "SecondaryOutcomeTimeFrame":"28 days (Dose 1) and 56 days (Dose 2)" },{ "SecondaryOutcomeMeasure":"Number/Percentage of Subjects With Seroconversion for Mucosal IgA", "SecondaryOutcomeDescription":"From nasal wick specimen. Seroconversion was defined as at least a four-fold rise after each dose from baseline or as the mean titer after each dose", "SecondaryOutcomeTimeFrame":"28 days (Dose 1) and 56 days (Dose 2)" },{ "SecondaryOutcomeMeasure":"Geometric Mean Titers (GMTs) for Serum Hemagglutination Inhibition (HAI) Antibodies (4 Haemagglutinating Units of H7N3)", "SecondaryOutcomeDescription":"HAI test was performed by standard procedure with human red blood cells utilizing either 4 haemagglutinating units (HAU) of H7N3.", "SecondaryOutcomeTimeFrame":"0 days, 28 days (Dose 1) and 56 days (Dose 2)" },{ "SecondaryOutcomeMeasure":"Geometric Mean Titers (GMTs) for Serum Hemagglutination Inhibition (HAI) Antibodies (2 Haemagglutinating Units of H7N3)", "SecondaryOutcomeDescription":"HAI test was performed by standard procedure with human red blood cells utilizing 2 haemagglutinating units (HAU) of H7N3.", "SecondaryOutcomeTimeFrame":"0 days, 28 days (Dose 1) and 56 days (Dose 2)" },{ "SecondaryOutcomeMeasure":"Geometric Mean Titers (GMTs) for Serum Neutralizing Antibodies", "SecondaryOutcomeDescription":"Measured by microneutralization assay", "SecondaryOutcomeTimeFrame":"0 days, 28 days (Dose 1) and 56 days (Dose 2)" },{ "SecondaryOutcomeMeasure":"Number/Percentage of Vaccinated Subjects Shedding Virus After First Dose", "SecondaryOutcomeDescription":"Detected by real-time reverse transcriptase polymerase chain reaction (rRTPCR) in nasal swabs or conjunctival swabs or by isolation in chicken embryos.", "SecondaryOutcomeTimeFrame":"Days 1, 2, 3 & 4" },{ "SecondaryOutcomeMeasure":"Number/Percentage of Subjects Shedding Virus After Second Dose", "SecondaryOutcomeDescription":"Detected by real-time reverse transcriptase polymerase chain reaction (rRTPCR) in nasal swabs or conjunctival swabs or by isolation in chicken embryos.", "SecondaryOutcomeTimeFrame":"Day 29, 30, 31 and 32" } ] }, "OtherOutcomeList":{ "OtherOutcome":[ { "OtherOutcomeMeasure":"Number/Percentage of Subjects Exhibiting CD4+ IFNγ+ Responses", "OtherOutcomeDescription":"H7N3-specific T cell responses were examined in peripheral blood mononuclear cells (PBMCs) obtained from all the study subjects before vaccination (Day 0), 28 days after the first vaccination (Day 28) and 28 days after revaccination (Day 56). To calculate the frequency of virus-specific T cells we quantified all cells positive for IFNγ after in vitro stimulation with whole H7N3 virion.\n\nIncreases in the antigen-specific CD4+T-cell levels exceeding 3 standard deviations from the levels in the mean of the placebo were considered positive responses.", "OtherOutcomeTimeFrame":"Days 0, 28 & 56" },{ "OtherOutcomeMeasure":"Number/Percentage of Subjects Exhibiting CD4+ IFNγ+ Central Memory T Cell Responses", "OtherOutcomeDescription":"H7N3-specific T cell responses were examined in PBMCs obtained from all the study subjects before vaccination (Day 0), 28 days after the first vaccination (Day 28) and 28 days after revaccination (Day 56). To calculate the frequency of virus-specific T cells we quantified all cells positive for IFNγ after in vitro stimulation with whole H7N3 virion.\n\nIncreases in the antigen-specific CD4+T-cell levels exceeding 3 standard deviations from the levels in the mean of the placebo were considered positive responses.", "OtherOutcomeTimeFrame":"Days 0, 28 & 56" },{ "OtherOutcomeMeasure":"Number/Percentage of Subjects Exhibiting CD4+ IFNγ+ Effector Memory T Cell Responses", "OtherOutcomeDescription":"H7N3-specific T cell responses were examined in PBMCs obtained from all the study subjects before vaccination (Day 0), 28 days after the first vaccination (Day 28) and 28 days after revaccination (Day 56). To calculate the frequency of virus-specific T cells we quantified all cells positive for IFNγ after in vitro stimulation with whole H7N3 virion.\n\nIncreases in the antigen-specific CD4+T-cell levels exceeding 3 standard deviations from the levels in the mean of the placebo were considered positive responses.", "OtherOutcomeTimeFrame":"Days 0, 28 & 56" },{ "OtherOutcomeMeasure":"Number/Percentage of Subjects Exhibiting CD8+ IFNγ+ Responses", "OtherOutcomeDescription":"H7N3-specific T cell responses were examined in PBMCs obtained from all the study subjects before vaccination (Day 0), 28 days after the first vaccination (Day 28) and 28 days after revaccination (Day 56). To calculate the frequency of virus-specific T cells we quantified all cells positive for IFNγ after in vitro stimulation with whole H7N3 virion.\n\nIncreases in the antigen-specific CD4+T-cell levels exceeding 3 standard deviations from the levels in the mean of the placebo were considered positive responses.", "OtherOutcomeTimeFrame":"Days 0, 28 & 56" },{ "OtherOutcomeMeasure":"Number/Percentage of Subjects Exhibiting CD8+ IFNγ+ Central Memory T Cell Responses", "OtherOutcomeDescription":"H7N3-specific T cell responses were examined in PBMCs obtained from all the study subjects before vaccination (Day 0), 28 days after the first vaccination (Day 28) and 28 days after revaccination (Day 56). To calculate the frequency of virus-specific T cells we quantified all cells positive for IFNγ after in vitro stimulation with whole H7N3 virion.\n\nIncreases in the antigen-specific CD4+T-cell levels exceeding 3 standard deviations from the levels in the mean of the placebo were considered positive responses.", "OtherOutcomeTimeFrame":"Days 0, 28 & 56" },{ "OtherOutcomeMeasure":"Number/Percentage of Subjects Exhibiting CD8+ IFNγ+ Effector Memory T Cell Responses", "OtherOutcomeDescription":"H7N3-specific T cell responses were examined in PBMCs obtained from all the study subjects before vaccination (Day 0), 28 days after the first vaccination (Day 28) and 28 days after revaccination (Day 56). To calculate the frequency of virus-specific T cells we quantified all cells positive for IFNγ after in vitro stimulation with whole H7N3 virion.\n\nIncreases in the antigen-specific CD4+T-cell levels exceeding 3 standard deviations from the levels in the mean of the placebo were considered positive responses.", "OtherOutcomeTimeFrame":"Days 0, 28 & 56" } ] } }, "EligibilityModule":{ "EligibilityCriteria":"Inclusion Criteria:\n\nLegal male or female adult 18 through 49 years of age at the enrollment visit.\nLiterate and willing to provide written informed consent.\nFree of obvious health problems, as established by the medical history and screening evaluations, including physical examination.\nCapable and willing to complete diary cards and willing to return for all follow-up visits\nWilling to comply with the rules of the isolation unit (including willing and able to take oseltamivir influenza antiviral medication, should that be recommended by a study physician).\nFor females, willing to take reliable birth control measures throughout the entire period of participation in the study.\n\nExclusion Criteria:\n\nParticipation in another clinical trial involving any therapy within the previous three months or planned enrollment in such a trial during the period of this study.\nReceipt of any non-study vaccine within four weeks prior to enrollment or refusal to postpone receipt of such vaccines until four weeks after study completion.\nPractice of nasal irrigation on a regular basis within the past six months or has engaged in nasal irrigation within two weeks prior to enrollment.\nRecent history of frequent nose bleeds (>5 within the past year).\nClinically relevant abnormal paranasal anatomy.\nRecent history (within the past month) of rhino or sinus surgery, or surgery for any traumatic injury of the nose.\nCurrent or recent (within two weeks of enrollment) acute respiratory illness with or without fever.\nOther acute illness at the time of study enrollment.\nReceipt of immune globulin or other blood products within three months prior to study enrollment or planned receipt of such products during the period of subject participation in the study.\nChronic administration (defined as more than 14 consecutively-prescribed days) of immunosuppressants or other immune-modulating therapy within six months prior to study enrollment. (For corticosteroids, this means prednisone or equivalent, >=0.5 mg per kg per day; topical steroids are allowed, exclusive of nasal.)\nParticipation in any previous trial of any H5 or H7 containing influenza vaccine.\nHistory of asthma.\nHypersensitivity after previous administration of any influenza vaccine.\nHistory of wheezing after past receipt of any live influenza vaccine.\nOther AE following immunization, at least possibly related to previous receipt of any influenza vaccine.\nSuspected or known hypersensitivity to any of the study vaccine components, including chicken or egg protein.\nSeasonal (autumnal) hypersensitivity to the natural environment.\nAcute or chronic clinically significant pulmonary, cardiovascular, hepatic, metabolic, neurologic, psychiatric or renal functional abnormality, as determined by medical history, physical examination or clinical laboratory screening tests, which in the opinion of the investigator, might interfere with the study objectives. Subjects with physical examination findings or clinical laboratory screening results which would be graded 2 or higher on the AE severity grading scale will be excluded from entry into the study and will be excluded from receipt of dose two of study vaccine or placebo.\nHistory of leukemia or any other blood or solid organ cancer.\nHistory of thrombocytopenic purpura or known bleeding disorder.\nHistory of seizures.\nKnown or suspected immunosuppressive or immunodeficient condition of any kind, including HIV infection.\nKnown chronic HBV or HCV infection.\nKnown tuberculosis infection or evidence of previous tuberculosis exposure.\nHistory of chronic alcohol abuse and/or illegal drug use.\nClaustrophobia or sociophobia.\nPregnancy or lactation. (A negative pregnancy test will be required before administration of study vaccine or placebo for all women of childbearing potential.)\nAny condition that, in the opinion of the investigator, would increase the health risk to the subject if he/she participates in the study or would interfere with the evaluation of the study objectives.", "HealthyVolunteers":"Accepts Healthy Volunteers", "Gender":"All", "MinimumAge":"18 Years", "MaximumAge":"49 Years", "StdAgeList":{ "StdAge":[ "Adult" ] } }, "ContactsLocationsModule":{ "OverallOfficialList":{ "OverallOfficial":[ { "OverallOfficialName":"Oleg I Kiselev, MD, PhD, DSc", "OverallOfficialAffiliation":"Research Institute of Influenza", "OverallOfficialRole":"Principal Investigator" },{ "OverallOfficialName":"Larisa G Rudenko, MD, PhD, DSc", "OverallOfficialAffiliation":"Institute of Experimental Medicine", "OverallOfficialRole":"Study Director" },{ "OverallOfficialName":"Kathleen M Neuzil, MD, MPH", "OverallOfficialAffiliation":"PATH Vaccine Solutions", "OverallOfficialRole":"Study Director" },{ "OverallOfficialName":"Igor Victorevich", "OverallOfficialAffiliation":"Microgen Scientific Industrial Company for Immunobiological Medicines", "OverallOfficialRole":"Study Director" } ] }, "LocationList":{ "Location":[ { "LocationFacility":"Research Institute of Influenza", "LocationCity":"St Petersburg", "LocationZip":"197376", "LocationCountry":"Russian Federation" } ] } }, "ReferencesModule":{ "ReferenceList":{ "Reference":[ { "ReferencePMID":"26432909", "ReferenceType":"derived", "ReferenceCitation":"Kiseleva I, Dubrovina I, Fedorova E, Larionova N, Isakova-Sivak I, Bazhenova E, Pisareva M, Kuznetsova V, Flores J, Rudenko L. Genetic stability of live attenuated vaccines against potentially pandemic influenza viruses. Vaccine. 2015 Dec 8;33(49):7008-14. doi: 10.1016/j.vaccine.2015.09.050. Epub 2015 Oct 2." },{ "ReferencePMID":"24533064", "ReferenceType":"derived", "ReferenceCitation":"Rudenko L, Kiseleva I, Naykhin AN, Erofeeva M, Stukova M, Donina S, Petukhova G, Pisareva M, Krivitskaya V, Grudinin M, Buzitskaya Z, Isakova-Sivak I, Kuznetsova S, Larionova N, Desheva J, Dubrovina I, Nikiforova A, Victor JC, Neuzil K, Flores J, Tsvetnitsky V, Kiselev O. Assessment of human immune responses to H7 avian influenza virus of pandemic potential: results from a placebo-controlled, randomized double-blind phase I study of live attenuated H7N3 influenza vaccine. PLoS One. 2014 Feb 12;9(2):e87962. doi: 10.1371/journal.pone.0087962. eCollection 2014." } ] } } }, "ResultsSection":{ "ParticipantFlowModule":{ "FlowGroupList":{ "FlowGroup":[ { "FlowGroupId":"FG000", "FlowGroupTitle":"LAIV H7N3", "FlowGroupDescription":"Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.\n\nName of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.\n\nDose: ≥7.5 log egg infectious dose (EID) 50/0.5 ml dose; 0.25 ml/nare.\n\nRoute of administration: Intranasal aerosol.\n\nDuration of treatment: Two doses were delivered, one on Day 0 and one on Day 28." },{ "FlowGroupId":"FG001", "FlowGroupTitle":"Placebo", "FlowGroupDescription":"Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.\n\nDose: 0.5 ml; 0.25 ml/nare\n\nRoute of administration: Intranasal aerosol\n\nDuration of treatment: Two doses were delivered, one on Day 0 and one on Day 28\n\nplacebo: 2 doses of placebo" } ] }, "FlowPeriodList":{ "FlowPeriod":[ { "FlowPeriodTitle":"Dose 1", "FlowMilestoneList":{ "FlowMilestone":[ { "FlowMilestoneType":"STARTED", "FlowAchievementList":{ "FlowAchievement":[ { "FlowAchievementGroupId":"FG000", "FlowAchievementNumSubjects":"30" },{ "FlowAchievementGroupId":"FG001", "FlowAchievementNumSubjects":"10" } ] } },{ "FlowMilestoneType":"COMPLETED", "FlowAchievementList":{ "FlowAchievement":[ { "FlowAchievementGroupId":"FG000", "FlowAchievementNumSubjects":"30" },{ "FlowAchievementGroupId":"FG001", "FlowAchievementNumSubjects":"10" } ] } },{ "FlowMilestoneType":"NOT COMPLETED", "FlowAchievementList":{ "FlowAchievement":[ { "FlowAchievementGroupId":"FG000", "FlowAchievementNumSubjects":"0" },{ "FlowAchievementGroupId":"FG001", "FlowAchievementNumSubjects":"0" } ] } } ] } },{ "FlowPeriodTitle":"Dose 2", "FlowMilestoneList":{ "FlowMilestone":[ { "FlowMilestoneType":"STARTED", "FlowAchievementList":{ "FlowAchievement":[ { "FlowAchievementGroupId":"FG000", "FlowAchievementNumSubjects":"30" },{ "FlowAchievementGroupId":"FG001", "FlowAchievementNumSubjects":"10" } ] } },{ "FlowMilestoneType":"COMPLETED", "FlowAchievementList":{ "FlowAchievement":[ { "FlowAchievementGroupId":"FG000", "FlowAchievementNumSubjects":"29" },{ "FlowAchievementGroupId":"FG001", "FlowAchievementNumSubjects":"10" } ] } },{ "FlowMilestoneType":"NOT COMPLETED", "FlowAchievementList":{ "FlowAchievement":[ { "FlowAchievementGroupId":"FG000", "FlowAchievementNumSubjects":"1" },{ "FlowAchievementGroupId":"FG001", "FlowAchievementNumSubjects":"0" } ] } } ] }, "FlowDropWithdrawList":{ "FlowDropWithdraw":[ { "FlowDropWithdrawType":"Physician Decision", "FlowReasonList":{ "FlowReason":[ { "FlowReasonGroupId":"FG000", "FlowReasonNumSubjects":"1" },{ "FlowReasonGroupId":"FG001", "FlowReasonNumSubjects":"0" } ] } } ] } } ] } }, "BaselineCharacteristicsModule":{ "BaselineGroupList":{ "BaselineGroup":[ { "BaselineGroupId":"BG000", "BaselineGroupTitle":"LAIV H7N3", "BaselineGroupDescription":"Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.\n\nName of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.\n\nDose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.\n\nRoute of administration: Intranasal aerosol.\n\nDuration of treatment: Two doses were delivered, one on Day 0 and one on Day 28.\n\nLAIV H7N3: 2 doses of vaccine" },{ "BaselineGroupId":"BG001", "BaselineGroupTitle":"Placebo", "BaselineGroupDescription":"Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.\n\nDose: 0.5 ml; 0.25 ml/nare\n\nRoute of administration: Intranasal aerosol\n\nDuration of treatment: Two doses were delivered, one on Day 0 and one on Day 28\n\nplacebo: 2 doses of placebo" },{ "BaselineGroupId":"BG002", "BaselineGroupTitle":"Total", "BaselineGroupDescription":"Total of all reporting groups" } ] }, "BaselineDenomList":{ "BaselineDenom":[ { "BaselineDenomUnits":"Participants", "BaselineDenomCountList":{ "BaselineDenomCount":[ { "BaselineDenomCountGroupId":"BG000", "BaselineDenomCountValue":"30" },{ "BaselineDenomCountGroupId":"BG001", "BaselineDenomCountValue":"10" },{ "BaselineDenomCountGroupId":"BG002", "BaselineDenomCountValue":"40" } ] } } ] }, "BaselineMeasureList":{ "BaselineMeasure":[ { "BaselineMeasureTitle":"Age, Continuous", "BaselineMeasureParamType":"Mean", "BaselineMeasureDispersionType":"Standard Deviation", "BaselineMeasureUnitOfMeasure":"years", "BaselineClassList":{ "BaselineClass":[ { "BaselineCategoryList":{ "BaselineCategory":[ { "BaselineMeasurementList":{ "BaselineMeasurement":[ { "BaselineMeasurementGroupId":"BG000", "BaselineMeasurementValue":"30.1", "BaselineMeasurementSpread":"10.3" },{ "BaselineMeasurementGroupId":"BG001", "BaselineMeasurementValue":"38.5", "BaselineMeasurementSpread":"9.7" },{ "BaselineMeasurementGroupId":"BG002", "BaselineMeasurementValue":"32.2", "BaselineMeasurementSpread":"10.7" } ] } } ] } } ] } },{ "BaselineMeasureTitle":"Sex: Female, Male", "BaselineMeasureParamType":"Count of Participants", "BaselineMeasureUnitOfMeasure":"Participants", "BaselineClassList":{ "BaselineClass":[ { "BaselineCategoryList":{ "BaselineCategory":[ { "BaselineCategoryTitle":"Female", "BaselineMeasurementList":{ "BaselineMeasurement":[ { "BaselineMeasurementGroupId":"BG000", "BaselineMeasurementValue":"15" },{ "BaselineMeasurementGroupId":"BG001", "BaselineMeasurementValue":"4" },{ "BaselineMeasurementGroupId":"BG002", "BaselineMeasurementValue":"19" } ] } },{ "BaselineCategoryTitle":"Male", "BaselineMeasurementList":{ "BaselineMeasurement":[ { "BaselineMeasurementGroupId":"BG000", "BaselineMeasurementValue":"15" },{ "BaselineMeasurementGroupId":"BG001", "BaselineMeasurementValue":"6" },{ "BaselineMeasurementGroupId":"BG002", "BaselineMeasurementValue":"21" } ] } } ] } } ] } } ] } }, "OutcomeMeasuresModule":{ "OutcomeMeasureList":{ "OutcomeMeasure":[ { "OutcomeMeasureType":"Primary", "OutcomeMeasureTitle":"Number of Participants With Immediate Reactions", "OutcomeMeasureDescription":"From administration of any dose, immediate reaction measured as observed by study staff or reported by the subject to study staff in case of an anaphylactic reaction.", "OutcomeMeasurePopulationDescription":"Intent-to-treat (ITT) population", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Count of Participants", "OutcomeMeasureUnitOfMeasure":"Participants", "OutcomeMeasureTimeFrame":"2 hours post-administration on Days 0 and 28", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"LAIV H7N3: Dose 1 (Day 0)", "OutcomeGroupDescription":"Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.\n\nName of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.\n\nDose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.\n\nRoute of administration: Intranasal aerosol." },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"Placebo: Dose 1 (Day 0)", "OutcomeGroupDescription":"Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.\n\nDose: 0.5 ml; 0.25 ml/nare\n\nRoute of administration: Intranasal aerosol" },{ "OutcomeGroupId":"OG002", "OutcomeGroupTitle":"LAIV H7N3: Dose 2 (Day 28)", "OutcomeGroupDescription":"Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.\n\nName of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.\n\nDose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.\n\nRoute of administration: Intranasal aerosol." },{ "OutcomeGroupId":"OG003", "OutcomeGroupTitle":"Placebo: Dose 2 (Day 28)", "OutcomeGroupDescription":"Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.\n\nDose: 0.5 ml; 0.25 ml/nare\n\nRoute of administration: Intranasal aerosol" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"30" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"10" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"29" },{ "OutcomeDenomCountGroupId":"OG003", "OutcomeDenomCountValue":"10" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeCategoryTitle":"Immediate reaction", "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG003", "OutcomeMeasurementValue":"0" } ] } },{ "OutcomeCategoryTitle":"No immediate reaction", "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"30" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"10" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"29" },{ "OutcomeMeasurementGroupId":"OG003", "OutcomeMeasurementValue":"10" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Primary", "OutcomeMeasureTitle":"Adverse Events Associated With Intranasal Vaccination", "OutcomeMeasureDescription":"From solicited local and systemic reactions", "OutcomeMeasurePopulationDescription":"Intent‐To‐Treat (ITT) Population", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Count of Participants", "OutcomeMeasureUnitOfMeasure":"Participants", "OutcomeMeasureTimeFrame":"Greater than 2 hours through 7 days following any dose", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"LAIV H7N3: Dose 1", "OutcomeGroupDescription":"Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.\n\nName of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.\n\nDose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.\n\nRoute of administration: Intranasal aerosol." },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"Placebo: Dose 1", "OutcomeGroupDescription":"Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.\n\nDose: 0.5 ml; 0.25 ml/nare\n\nRoute of administration: Intranasal aerosol" },{ "OutcomeGroupId":"OG002", "OutcomeGroupTitle":"LAIV H7N3: Dose 2", "OutcomeGroupDescription":"Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.\n\nName of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.\n\nDose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.\n\nRoute of administration: Intranasal aerosol." },{ "OutcomeGroupId":"OG003", "OutcomeGroupTitle":"Placebo: Dose 2", "OutcomeGroupDescription":"Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.\n\nDose: 0.5 ml; 0.25 ml/nare\n\nRoute of administration: Intranasal aerosol" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"30" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"10" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"29" },{ "OutcomeDenomCountGroupId":"OG003", "OutcomeDenomCountValue":"10" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeCategoryTitle":"Any local or systemic reaction", "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"11" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"4" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"5" },{ "OutcomeMeasurementGroupId":"OG003", "OutcomeMeasurementValue":"1" } ] } },{ "OutcomeCategoryTitle":"No local or systemic reaction", "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"19" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"6" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"24" },{ "OutcomeMeasurementGroupId":"OG003", "OutcomeMeasurementValue":"9" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Primary", "OutcomeMeasureTitle":"All Other Adverse Events", "OutcomeMeasureDescription":"Including unsolicited events and abnormal laboratory findings", "OutcomeMeasurePopulationDescription":"Total events among Intent‐To‐Treat (ITT) Population", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Count of Units", "OutcomeMeasureUnitOfMeasure":"adverse events", "OutcomeMeasureTimeFrame":"7 days following any dose", "OutcomeMeasureTypeUnitsAnalyzed":"adverse events", "OutcomeMeasureDenomUnitsSelected":"adverse events", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"LAIV H7N3: Dose 1", "OutcomeGroupDescription":"Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.\n\nName of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.\n\nDose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.\n\nRoute of administration: Intranasal aerosol." },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"Placebo: Dose 1", "OutcomeGroupDescription":"Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.\n\nDose: 0.5 ml; 0.25 ml/nare\n\nRoute of administration: Intranasal aerosol" },{ "OutcomeGroupId":"OG002", "OutcomeGroupTitle":"LAIV H7N3: Dose 2", "OutcomeGroupDescription":"Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.\n\nName of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.\n\nDose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.\n\nRoute of administration: Intranasal aerosol." },{ "OutcomeGroupId":"OG003", "OutcomeGroupTitle":"Placebo: Dose 2", "OutcomeGroupDescription":"Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.\n\nDose: 0.5 ml; 0.25 ml/nare\n\nRoute of administration: Intranasal aerosol" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"30" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"10" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"29" },{ "OutcomeDenomCountGroupId":"OG003", "OutcomeDenomCountValue":"10" } ] } },{ "OutcomeDenomUnits":"adverse events", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"44" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"6" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"90" },{ "OutcomeDenomCountGroupId":"OG003", "OutcomeDenomCountValue":"21" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeClassTitle":"Unrelated", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"40" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"6" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"84" },{ "OutcomeMeasurementGroupId":"OG003", "OutcomeMeasurementValue":"20" } ] } } ] } },{ "OutcomeClassTitle":"Related", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"4" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"6" },{ "OutcomeMeasurementGroupId":"OG003", "OutcomeMeasurementValue":"1" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Primary", "OutcomeMeasureTitle":"Participants With Serious Adverse Events (SAEs)", "OutcomeMeasureDescription":"Including abnormal laboratory findings", "OutcomeMeasurePopulationDescription":"Intent‐To‐Treat (ITT) Population", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Count of Participants", "OutcomeMeasureUnitOfMeasure":"Participants", "OutcomeMeasureTimeFrame":"Within 4 weeks of receipt of any dose", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"LAIV H7N3: Dose 1", "OutcomeGroupDescription":"Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.\n\nName of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.\n\nDose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.\n\nRoute of administration: Intranasal aerosol." },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"Placebo: Dose 1", "OutcomeGroupDescription":"Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.\n\nDose: 0.5 ml; 0.25 ml/nare\n\nRoute of administration: Intranasal aerosol" },{ "OutcomeGroupId":"OG002", "OutcomeGroupTitle":"LAIV H7N3: Dose 2", "OutcomeGroupDescription":"Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.\n\nName of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.\n\nDose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.\n\nRoute of administration: Intranasal aerosol." },{ "OutcomeGroupId":"OG003", "OutcomeGroupTitle":"Placebo: Dose 2", "OutcomeGroupDescription":"Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.\n\nDose: 0.5 ml; 0.25 ml/nare\n\nRoute of administration: Intranasal aerosol" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"30" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"10" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"29" },{ "OutcomeDenomCountGroupId":"OG003", "OutcomeDenomCountValue":"10" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeCategoryTitle":"Any serious adverse event", "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG003", "OutcomeMeasurementValue":"0" } ] } },{ "OutcomeCategoryTitle":"No serious adverse event", "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"30" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"10" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"29" },{ "OutcomeMeasurementGroupId":"OG003", "OutcomeMeasurementValue":"10" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Secondary", "OutcomeMeasureTitle":"Number/Percentage of Subjects With Seroconversion for Serum Hemagglutination Inhibition (HAI)", "OutcomeMeasureDescription":"Seroconversion was defined as at least a four-fold rise after each dose from baseline or as the mean titer after each dose", "OutcomeMeasurePopulationDescription":"Per-Protocol (PP) Population", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Count of Participants", "OutcomeMeasureUnitOfMeasure":"Participants", "OutcomeMeasureTimeFrame":"28 days (Dose 1) and 56 days (Dose 2)", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"LAIV H7N3: Dose 1", "OutcomeGroupDescription":"Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.\n\nName of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.\n\nDose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.\n\nRoute of administration: Intranasal aerosol." },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"Placebo: Dose 1", "OutcomeGroupDescription":"Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.\n\nDose: 0.5 ml; 0.25 ml/nare\n\nRoute of administration: Intranasal aerosol" },{ "OutcomeGroupId":"OG002", "OutcomeGroupTitle":"LAIV H7N3: Dose 2", "OutcomeGroupDescription":"Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.\n\nName of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.\n\nDose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.\n\nRoute of administration: Intranasal aerosol." },{ "OutcomeGroupId":"OG003", "OutcomeGroupTitle":"Placebo: Dose 2", "OutcomeGroupDescription":"Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.\n\nDose: 0.5 ml; 0.25 ml/nare\n\nRoute of administration: Intranasal aerosol" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"29" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"10" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"29" },{ "OutcomeDenomCountGroupId":"OG003", "OutcomeDenomCountValue":"10" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeCategoryTitle":"Seroconversion", "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"3" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"9" },{ "OutcomeMeasurementGroupId":"OG003", "OutcomeMeasurementValue":"0" } ] } },{ "OutcomeCategoryTitle":"No seroconversion", "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"26" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"10" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"20" },{ "OutcomeMeasurementGroupId":"OG003", "OutcomeMeasurementValue":"10" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Secondary", "OutcomeMeasureTitle":"Number/Percentage of Subjects With Serum Neutralizing Antibodies", "OutcomeMeasureDescription":"Measured using microneutralization assay. Seroconversion was defined as at least a four-fold rise after each dose from baseline or as the mean titer after each dose", "OutcomeMeasurePopulationDescription":"Per-Protocol (PP) Population", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Count of Participants", "OutcomeMeasureUnitOfMeasure":"Participants", "OutcomeMeasureTimeFrame":"28 days (Dose 1) and 56 days (Dose 2)", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"LAIV H7N3: Dose 1", "OutcomeGroupDescription":"Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.\n\nName of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.\n\nDose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.\n\nRoute of administration: Intranasal aerosol." },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"Placebo: Dose 1", "OutcomeGroupDescription":"Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.\n\nDose: 0.5 ml; 0.25 ml/nare\n\nRoute of administration: Intranasal aerosol" },{ "OutcomeGroupId":"OG002", "OutcomeGroupTitle":"LAIV H7N3: Dose 2", "OutcomeGroupDescription":"Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.\n\nName of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.\n\nDose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.\n\nRoute of administration: Intranasal aerosol." },{ "OutcomeGroupId":"OG003", "OutcomeGroupTitle":"Placebo: Dose 2", "OutcomeGroupDescription":"Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.\n\nDose: 0.5 ml; 0.25 ml/nare\n\nRoute of administration: Intranasal aerosol" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"29" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"10" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"29" },{ "OutcomeDenomCountGroupId":"OG003", "OutcomeDenomCountValue":"10" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeCategoryTitle":"Seroconversion", "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"5" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"12" },{ "OutcomeMeasurementGroupId":"OG003", "OutcomeMeasurementValue":"0" } ] } },{ "OutcomeCategoryTitle":"No seroconversion", "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"24" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"10" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"17" },{ "OutcomeMeasurementGroupId":"OG003", "OutcomeMeasurementValue":"10" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Secondary", "OutcomeMeasureTitle":"Number/Percentage of Subjects With Seroconversion for Serum Immunoglobulin A (IgA)", "OutcomeMeasureDescription":"Measured by enzyme-linked immunoassay (EIA). Seroconversion was defined as at least a four-fold rise after each dose from baseline or as the mean titer after each dose", "OutcomeMeasurePopulationDescription":"Per-Protocol (PP) Population", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Count of Participants", "OutcomeMeasureUnitOfMeasure":"Participants", "OutcomeMeasureTimeFrame":"28 days (Dose 1) and 56 days (Dose 2)", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"LAIV H7N3: Dose 1", "OutcomeGroupDescription":"Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.\n\nName of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.\n\nDose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.\n\nRoute of administration: Intranasal aerosol." },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"Placebo: Dose 1", "OutcomeGroupDescription":"Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.\n\nDose: 0.5 ml; 0.25 ml/nare\n\nRoute of administration: Intranasal aerosol" },{ "OutcomeGroupId":"OG002", "OutcomeGroupTitle":"LAIV H7N3: Dose 2", "OutcomeGroupDescription":"Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.\n\nName of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.\n\nDose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.\n\nRoute of administration: Intranasal aerosol." },{ "OutcomeGroupId":"OG003", "OutcomeGroupTitle":"Placebo: Dose 2", "OutcomeGroupDescription":"Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.\n\nDose: 0.5 ml; 0.25 ml/nare\n\nRoute of administration: Intranasal aerosol" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"29" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"10" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"29" },{ "OutcomeDenomCountGroupId":"OG003", "OutcomeDenomCountValue":"10" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeCategoryTitle":"Seroconversion", "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"3" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"8" },{ "OutcomeMeasurementGroupId":"OG003", "OutcomeMeasurementValue":"0" } ] } },{ "OutcomeCategoryTitle":"No seroconversion", "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"26" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"10" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"21" },{ "OutcomeMeasurementGroupId":"OG003", "OutcomeMeasurementValue":"10" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Secondary", "OutcomeMeasureTitle":"Number/Percentage of Subjects With Seroconversion for Serum Immunoglobulin G (IgG)", "OutcomeMeasureDescription":"Measured by enzyme-linked immunoassay (EIA). Seroconversion was defined as at least a four-fold rise after each dose from baseline or as the mean titer after each dose", "OutcomeMeasurePopulationDescription":"Per-Protocol (PP) Population", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Count of Participants", "OutcomeMeasureUnitOfMeasure":"Participants", "OutcomeMeasureTimeFrame":"28 days (Dose 1) and 56 days (Dose 2)", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"LAIV H7N3: Dose 1", "OutcomeGroupDescription":"Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.\n\nName of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.\n\nDose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.\n\nRoute of administration: Intranasal aerosol." },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"Placebo: Dose 1", "OutcomeGroupDescription":"Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.\n\nDose: 0.5 ml; 0.25 ml/nare\n\nRoute of administration: Intranasal aerosol" },{ "OutcomeGroupId":"OG002", "OutcomeGroupTitle":"LAIV H7N3: Dose 2", "OutcomeGroupDescription":"Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.\n\nName of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.\n\nDose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.\n\nRoute of administration: Intranasal aerosol." },{ "OutcomeGroupId":"OG003", "OutcomeGroupTitle":"Placebo: Dose 2", "OutcomeGroupDescription":"Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.\n\nDose: 0.5 ml; 0.25 ml/nare\n\nRoute of administration: Intranasal aerosol" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"29" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"10" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"29" },{ "OutcomeDenomCountGroupId":"OG003", "OutcomeDenomCountValue":"10" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeCategoryTitle":"Seroconversion", "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"1" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"3" },{ "OutcomeMeasurementGroupId":"OG003", "OutcomeMeasurementValue":"0" } ] } },{ "OutcomeCategoryTitle":"No seroconversion", "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"28" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"10" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"26" },{ "OutcomeMeasurementGroupId":"OG003", "OutcomeMeasurementValue":"10" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Secondary", "OutcomeMeasureTitle":"Number/Percentage of Subjects With Seroconversion for Mucosal IgA", "OutcomeMeasureDescription":"From nasal wick specimen. Seroconversion was defined as at least a four-fold rise after each dose from baseline or as the mean titer after each dose", "OutcomeMeasurePopulationDescription":"Per-Protocol (PP) Population", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Count of Participants", "OutcomeMeasureUnitOfMeasure":"Participants", "OutcomeMeasureTimeFrame":"28 days (Dose 1) and 56 days (Dose 2)", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"LAIV H7N3: Dose 1", "OutcomeGroupDescription":"Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.\n\nName of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.\n\nDose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.\n\nRoute of administration: Intranasal aerosol." },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"Placebo: Dose 1", "OutcomeGroupDescription":"Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.\n\nDose: 0.5 ml; 0.25 ml/nare\n\nRoute of administration: Intranasal aerosol" },{ "OutcomeGroupId":"OG002", "OutcomeGroupTitle":"LAIV H7N3: Dose 2", "OutcomeGroupDescription":"Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.\n\nName of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.\n\nDose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.\n\nRoute of administration: Intranasal aerosol." },{ "OutcomeGroupId":"OG003", "OutcomeGroupTitle":"Placebo: Dose 2", "OutcomeGroupDescription":"Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.\n\nDose: 0.5 ml; 0.25 ml/nare\n\nRoute of administration: Intranasal aerosol" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"29" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"10" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"29" },{ "OutcomeDenomCountGroupId":"OG003", "OutcomeDenomCountValue":"10" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeCategoryTitle":"Seroconversion", "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"12" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"1" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"12" },{ "OutcomeMeasurementGroupId":"OG003", "OutcomeMeasurementValue":"1" } ] } },{ "OutcomeCategoryTitle":"No seroconversion", "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"17" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"9" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"17" },{ "OutcomeMeasurementGroupId":"OG003", "OutcomeMeasurementValue":"9" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Secondary", "OutcomeMeasureTitle":"Geometric Mean Titers (GMTs) for Serum Hemagglutination Inhibition (HAI) Antibodies (4 Haemagglutinating Units of H7N3)", "OutcomeMeasureDescription":"HAI test was performed by standard procedure with human red blood cells utilizing either 4 haemagglutinating units (HAU) of H7N3.", "OutcomeMeasurePopulationDescription":"Per-Protocol (PP) Population", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Geometric Mean", "OutcomeMeasureDispersionType":"95% Confidence Interval", "OutcomeMeasureUnitOfMeasure":"titers", "OutcomeMeasureTimeFrame":"0 days, 28 days (Dose 1) and 56 days (Dose 2)", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"LAIV H7N3", "OutcomeGroupDescription":"Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.\n\nName of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.\n\nDose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.\n\nRoute of administration: Intranasal aerosol.\n\nDuration of treatment: Two doses were delivered, one on Day 0 and one on Day 28.\n\nLAIV H7N3: 2 doses of vaccine" },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"Placebo", "OutcomeGroupDescription":"Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.\n\nDose: 0.5 ml; 0.25 ml/nare\n\nRoute of administration: Intranasal aerosol\n\nDuration of treatment: Two doses were delivered, one on Day 0 and one on Day 28\n\nplacebo: 2 doses of placebo" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"29" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"10" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeClassTitle":"Day 0", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"2.8", "OutcomeMeasurementLowerLimit":"2.5", "OutcomeMeasurementUpperLimit":"3.1" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"3.3", "OutcomeMeasurementLowerLimit":"2.3", "OutcomeMeasurementUpperLimit":"4.7" } ] } } ] } },{ "OutcomeClassTitle":"Day 28", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"3.5", "OutcomeMeasurementLowerLimit":"2.8", "OutcomeMeasurementUpperLimit":"4.4" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"3.3", "OutcomeMeasurementLowerLimit":"2.3", "OutcomeMeasurementUpperLimit":"4.7" } ] } } ] } },{ "OutcomeClassTitle":"Day 56", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"4.7", "OutcomeMeasurementLowerLimit":"3.5", "OutcomeMeasurementUpperLimit":"6.1" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"3.5", "OutcomeMeasurementLowerLimit":"2.5", "OutcomeMeasurementUpperLimit":"5.0" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Secondary", "OutcomeMeasureTitle":"Geometric Mean Titers (GMTs) for Serum Hemagglutination Inhibition (HAI) Antibodies (2 Haemagglutinating Units of H7N3)", "OutcomeMeasureDescription":"HAI test was performed by standard procedure with human red blood cells utilizing 2 haemagglutinating units (HAU) of H7N3.", "OutcomeMeasurePopulationDescription":"Per-Protocol (PP) population", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Geometric Mean", "OutcomeMeasureDispersionType":"95% Confidence Interval", "OutcomeMeasureUnitOfMeasure":"titer", "OutcomeMeasureTimeFrame":"0 days, 28 days (Dose 1) and 56 days (Dose 2)", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"LAIV H7N3", "OutcomeGroupDescription":"Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.\n\nName of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.\n\nDose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.\n\nRoute of administration: Intranasal aerosol.\n\nDuration of treatment: Two doses were delivered, one on Day 0 and one on Day 28.\n\nLAIV H7N3: 2 doses of vaccine" },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"Placebo", "OutcomeGroupDescription":"Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.\n\nDose: 0.5 ml; 0.25 ml/nare\n\nRoute of administration: Intranasal aerosol\n\nDuration of treatment: Two doses were delivered, one on Day 0 and one on Day 28\n\nplacebo: 2 doses of placebo" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"29" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"10" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeClassTitle":"Day 0", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"3.0", "OutcomeMeasurementLowerLimit":"2.6", "OutcomeMeasurementUpperLimit":"3.5" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"4.1", "OutcomeMeasurementLowerLimit":"2.7", "OutcomeMeasurementUpperLimit":"6.1" } ] } } ] } },{ "OutcomeClassTitle":"Day 28", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"5.5", "OutcomeMeasurementLowerLimit":"4.2", "OutcomeMeasurementUpperLimit":"7.2" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"4.1", "OutcomeMeasurementLowerLimit":"2.7", "OutcomeMeasurementUpperLimit":"6.1" } ] } } ] } },{ "OutcomeClassTitle":"Day 56", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"7", "OutcomeMeasurementLowerLimit":"5.2", "OutcomeMeasurementUpperLimit":"9.4" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"4.7", "OutcomeMeasurementLowerLimit":"2.8", "OutcomeMeasurementUpperLimit":"7.6" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Secondary", "OutcomeMeasureTitle":"Geometric Mean Titers (GMTs) for Serum Neutralizing Antibodies", "OutcomeMeasureDescription":"Measured by microneutralization assay", "OutcomeMeasurePopulationDescription":"Per-Protocol (PP) population", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Geometric Mean", "OutcomeMeasureDispersionType":"95% Confidence Interval", "OutcomeMeasureUnitOfMeasure":"titer", "OutcomeMeasureTimeFrame":"0 days, 28 days (Dose 1) and 56 days (Dose 2)", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"LAIV H7N3", "OutcomeGroupDescription":"Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.\n\nName of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.\n\nDose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.\n\nRoute of administration: Intranasal aerosol.\n\nDuration of treatment: Two doses were delivered, one on Day 0 and one on Day 28.\n\nLAIV H7N3: 2 doses of vaccine" },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"Placebo", "OutcomeGroupDescription":"Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.\n\nDose: 0.5 ml; 0.25 ml/nare\n\nRoute of administration: Intranasal aerosol\n\nDuration of treatment: Two doses were delivered, one on Day 0 and one on Day 28\n\nplacebo: 2 doses of placebo" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"29" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"10" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeClassTitle":"Day 0", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"4.2", "OutcomeMeasurementLowerLimit":"3.5", "OutcomeMeasurementUpperLimit":"5.1" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"4.4", "OutcomeMeasurementLowerLimit":"2.8", "OutcomeMeasurementUpperLimit":"6.9" } ] } } ] } },{ "OutcomeClassTitle":"Day 28", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"6.2", "OutcomeMeasurementLowerLimit":"4.5", "OutcomeMeasurementUpperLimit":"8.5" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"4.4", "OutcomeMeasurementLowerLimit":"2.8", "OutcomeMeasurementUpperLimit":"6.9" } ] } } ] } },{ "OutcomeClassTitle":"Day 56", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"12.4", "OutcomeMeasurementLowerLimit":"8.2", "OutcomeMeasurementUpperLimit":"18.7" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"5.0", "OutcomeMeasurementLowerLimit":"3.1", "OutcomeMeasurementUpperLimit":"8.0" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Secondary", "OutcomeMeasureTitle":"Number/Percentage of Vaccinated Subjects Shedding Virus After First Dose", "OutcomeMeasureDescription":"Detected by real-time reverse transcriptase polymerase chain reaction (rRTPCR) in nasal swabs or conjunctival swabs or by isolation in chicken embryos.", "OutcomeMeasurePopulationDescription":"Intent-To-Treat (ITT) Population", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Count of Participants", "OutcomeMeasureUnitOfMeasure":"Participants", "OutcomeMeasureTimeFrame":"Days 1, 2, 3 & 4", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"Day 1", "OutcomeGroupDescription":"LAIV H7N3 Arm" },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"Day 2", "OutcomeGroupDescription":"LAIV H7N3 Arm" },{ "OutcomeGroupId":"OG002", "OutcomeGroupTitle":"Day 3", "OutcomeGroupDescription":"LAIV H7N3 Arm" },{ "OutcomeGroupId":"OG003", "OutcomeGroupTitle":"Day 4", "OutcomeGroupDescription":"LAIV H7N3 Arm" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"30" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"30" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"30" },{ "OutcomeDenomCountGroupId":"OG003", "OutcomeDenomCountValue":"30" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeCategoryTitle":"Shedding", "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"18" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"3" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"1" },{ "OutcomeMeasurementGroupId":"OG003", "OutcomeMeasurementValue":"0" } ] } },{ "OutcomeCategoryTitle":"No shedding", "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"12" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"27" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"29" },{ "OutcomeMeasurementGroupId":"OG003", "OutcomeMeasurementValue":"30" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Secondary", "OutcomeMeasureTitle":"Number/Percentage of Subjects Shedding Virus After Second Dose", "OutcomeMeasureDescription":"Detected by real-time reverse transcriptase polymerase chain reaction (rRTPCR) in nasal swabs or conjunctival swabs or by isolation in chicken embryos.", "OutcomeMeasurePopulationDescription":"Per‐Protocol (PP) Population", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Count of Participants", "OutcomeMeasureUnitOfMeasure":"Participants", "OutcomeMeasureTimeFrame":"Day 29, 30, 31 and 32", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"Day 29", "OutcomeGroupDescription":"LAIV H7N3 Arm" },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"Day 30", "OutcomeGroupDescription":"LAIV H7N3 Arm" },{ "OutcomeGroupId":"OG002", "OutcomeGroupTitle":"Day 31", "OutcomeGroupDescription":"LAIV H7N3 Arm" },{ "OutcomeGroupId":"OG003", "OutcomeGroupTitle":"Day 32", "OutcomeGroupDescription":"LAIV H7N3 Arm" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"29" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"29" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"29" },{ "OutcomeDenomCountGroupId":"OG003", "OutcomeDenomCountValue":"29" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeCategoryTitle":"Shedding", "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"14" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"2" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"1" },{ "OutcomeMeasurementGroupId":"OG003", "OutcomeMeasurementValue":"0" } ] } },{ "OutcomeCategoryTitle":"No shedding", "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"15" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"27" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"28" },{ "OutcomeMeasurementGroupId":"OG003", "OutcomeMeasurementValue":"29" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Other Pre-specified", "OutcomeMeasureTitle":"Number/Percentage of Subjects Exhibiting CD4+ IFNγ+ Responses", "OutcomeMeasureDescription":"H7N3-specific T cell responses were examined in peripheral blood mononuclear cells (PBMCs) obtained from all the study subjects before vaccination (Day 0), 28 days after the first vaccination (Day 28) and 28 days after revaccination (Day 56). To calculate the frequency of virus-specific T cells we quantified all cells positive for IFNγ after in vitro stimulation with whole H7N3 virion.\n\nIncreases in the antigen-specific CD4+T-cell levels exceeding 3 standard deviations from the levels in the mean of the placebo were considered positive responses.", "OutcomeMeasurePopulationDescription":"Per-Protocol (PP) population that received 2 doses of either vaccine or placebo", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Count of Participants", "OutcomeMeasureUnitOfMeasure":"Participants", "OutcomeMeasureTimeFrame":"Days 0, 28 & 56", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"LAIV H7N3: Day 0 (After Dose 1)", "OutcomeGroupDescription":"Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.\n\nName of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.\n\nDose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.\n\nRoute of administration: Intranasal aerosol." },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"Placebo: Day 0 (After Dose 1)", "OutcomeGroupDescription":"Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.\n\nDose: 0.5 ml; 0.25 ml/nare\n\nRoute of administration: Intranasal aerosol" },{ "OutcomeGroupId":"OG002", "OutcomeGroupTitle":"LAIV H7N3: Day 28 (Dose 2)", "OutcomeGroupDescription":"Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.\n\nName of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.\n\nDose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.\n\nRoute of administration: Intranasal aerosol." },{ "OutcomeGroupId":"OG003", "OutcomeGroupTitle":"Placebo: Day 28 (Dose 2)", "OutcomeGroupDescription":"Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.\n\nDose: 0.5 ml; 0.25 ml/nare\n\nRoute of administration: Intranasal aerosol" },{ "OutcomeGroupId":"OG004", "OutcomeGroupTitle":"LAIV H7N3: Day 56 (28 Days Past Dose 2)", "OutcomeGroupDescription":"Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.\n\nName of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.\n\nDose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.\n\nRoute of administration: Intranasal aerosol." },{ "OutcomeGroupId":"OG005", "OutcomeGroupTitle":"Placebo: Day 56 (28 Days Past Dose 2)", "OutcomeGroupDescription":"Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.\n\nDose: 0.5 ml; 0.25 ml/nare\n\nRoute of administration: Intranasal aerosol" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"29" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"10" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"29" },{ "OutcomeDenomCountGroupId":"OG003", "OutcomeDenomCountValue":"10" },{ "OutcomeDenomCountGroupId":"OG004", "OutcomeDenomCountValue":"29" },{ "OutcomeDenomCountGroupId":"OG005", "OutcomeDenomCountValue":"10" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeCategoryTitle":"Positive response", "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"2" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"3" },{ "OutcomeMeasurementGroupId":"OG003", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG004", "OutcomeMeasurementValue":"4" },{ "OutcomeMeasurementGroupId":"OG005", "OutcomeMeasurementValue":"0" } ] } },{ "OutcomeCategoryTitle":"No response", "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"27" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"10" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"26" },{ "OutcomeMeasurementGroupId":"OG003", "OutcomeMeasurementValue":"10" },{ "OutcomeMeasurementGroupId":"OG004", "OutcomeMeasurementValue":"25" },{ "OutcomeMeasurementGroupId":"OG005", "OutcomeMeasurementValue":"10" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Other Pre-specified", "OutcomeMeasureTitle":"Number/Percentage of Subjects Exhibiting CD4+ IFNγ+ Central Memory T Cell Responses", "OutcomeMeasureDescription":"H7N3-specific T cell responses were examined in PBMCs obtained from all the study subjects before vaccination (Day 0), 28 days after the first vaccination (Day 28) and 28 days after revaccination (Day 56). To calculate the frequency of virus-specific T cells we quantified all cells positive for IFNγ after in vitro stimulation with whole H7N3 virion.\n\nIncreases in the antigen-specific CD4+T-cell levels exceeding 3 standard deviations from the levels in the mean of the placebo were considered positive responses.", "OutcomeMeasurePopulationDescription":"Per-Protocol (PP) population that received 2 doses of either vaccine or placebo", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Count of Participants", "OutcomeMeasureUnitOfMeasure":"Participants", "OutcomeMeasureTimeFrame":"Days 0, 28 & 56", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"LAIV H7N3: Day 0 (After Dose 1)", "OutcomeGroupDescription":"Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.\n\nName of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.\n\nDose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.\n\nRoute of administration: Intranasal aerosol." },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"Placebo: Day 0 (After Dose 1)", "OutcomeGroupDescription":"Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.\n\nDose: 0.5 ml; 0.25 ml/nare\n\nRoute of administration: Intranasal aerosol" },{ "OutcomeGroupId":"OG002", "OutcomeGroupTitle":"LAIV H7N3: Day 28 (Dose 2)", "OutcomeGroupDescription":"Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.\n\nName of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.\n\nDose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.\n\nRoute of administration: Intranasal aerosol." },{ "OutcomeGroupId":"OG003", "OutcomeGroupTitle":"Placebo: Day 28 (Dose 2)", "OutcomeGroupDescription":"Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.\n\nDose: 0.5 ml; 0.25 ml/nare\n\nRoute of administration: Intranasal aerosol" },{ "OutcomeGroupId":"OG004", "OutcomeGroupTitle":"LAIV H7N3: Day 56 (28 Days Past Dose 2)", "OutcomeGroupDescription":"Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.\n\nName of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.\n\nDose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.\n\nRoute of administration: Intranasal aerosol." },{ "OutcomeGroupId":"OG005", "OutcomeGroupTitle":"Placebo: Day 56 (28 Days Past Dose 2)", "OutcomeGroupDescription":"Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.\n\nDose: 0.5 ml; 0.25 ml/nare\n\nRoute of administration: Intranasal aerosol" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"29" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"10" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"29" },{ "OutcomeDenomCountGroupId":"OG003", "OutcomeDenomCountValue":"10" },{ "OutcomeDenomCountGroupId":"OG004", "OutcomeDenomCountValue":"29" },{ "OutcomeDenomCountGroupId":"OG005", "OutcomeDenomCountValue":"10" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeCategoryTitle":"Positive response", "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"5" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"6" },{ "OutcomeMeasurementGroupId":"OG003", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG004", "OutcomeMeasurementValue":"7" },{ "OutcomeMeasurementGroupId":"OG005", "OutcomeMeasurementValue":"0" } ] } },{ "OutcomeCategoryTitle":"No response", "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"24" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"10" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"23" },{ "OutcomeMeasurementGroupId":"OG003", "OutcomeMeasurementValue":"10" },{ "OutcomeMeasurementGroupId":"OG004", "OutcomeMeasurementValue":"22" },{ "OutcomeMeasurementGroupId":"OG005", "OutcomeMeasurementValue":"10" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Other Pre-specified", "OutcomeMeasureTitle":"Number/Percentage of Subjects Exhibiting CD4+ IFNγ+ Effector Memory T Cell Responses", "OutcomeMeasureDescription":"H7N3-specific T cell responses were examined in PBMCs obtained from all the study subjects before vaccination (Day 0), 28 days after the first vaccination (Day 28) and 28 days after revaccination (Day 56). To calculate the frequency of virus-specific T cells we quantified all cells positive for IFNγ after in vitro stimulation with whole H7N3 virion.\n\nIncreases in the antigen-specific CD4+T-cell levels exceeding 3 standard deviations from the levels in the mean of the placebo were considered positive responses.", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Count of Participants", "OutcomeMeasureUnitOfMeasure":"Participants", "OutcomeMeasureTimeFrame":"Days 0, 28 & 56", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"LAIV H7N3: Dose 1 (Day 0)", "OutcomeGroupDescription":"Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.\n\nName of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.\n\nDose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.\n\nRoute of administration: Intranasal aerosol." },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"Placebo: Dose 1 (Day 0)", "OutcomeGroupDescription":"Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.\n\nDose: 0.5 ml; 0.25 ml/nare\n\nRoute of administration: Intranasal aerosol" },{ "OutcomeGroupId":"OG002", "OutcomeGroupTitle":"LAIV H7N3: Day 28 (Dose 2)", "OutcomeGroupDescription":"Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.\n\nName of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.\n\nDose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.\n\nRoute of administration: Intranasal aerosol." },{ "OutcomeGroupId":"OG003", "OutcomeGroupTitle":"Placebo: Day 28 (Dose 2)", "OutcomeGroupDescription":"Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.\n\nDose: 0.5 ml; 0.25 ml/nare\n\nRoute of administration: Intranasal aerosol" },{ "OutcomeGroupId":"OG004", "OutcomeGroupTitle":"LAIV H7N3: Day 56 (28 Days Past Dose 2)", "OutcomeGroupDescription":"Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.\n\nName of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.\n\nDose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.\n\nRoute of administration: Intranasal aerosol." },{ "OutcomeGroupId":"OG005", "OutcomeGroupTitle":"Placebo: Day 56 (28 Days Past Dose 2)", "OutcomeGroupDescription":"Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.\n\nDose: 0.5 ml; 0.25 ml/nare\n\nRoute of administration: Intranasal aerosol" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"29" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"10" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"29" },{ "OutcomeDenomCountGroupId":"OG003", "OutcomeDenomCountValue":"10" },{ "OutcomeDenomCountGroupId":"OG004", "OutcomeDenomCountValue":"29" },{ "OutcomeDenomCountGroupId":"OG005", "OutcomeDenomCountValue":"10" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeCategoryTitle":"Positive response", "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"1" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"3" },{ "OutcomeMeasurementGroupId":"OG003", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG004", "OutcomeMeasurementValue":"3" },{ "OutcomeMeasurementGroupId":"OG005", "OutcomeMeasurementValue":"0" } ] } },{ "OutcomeCategoryTitle":"No response", "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"28" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"10" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"26" },{ "OutcomeMeasurementGroupId":"OG003", "OutcomeMeasurementValue":"10" },{ "OutcomeMeasurementGroupId":"OG004", "OutcomeMeasurementValue":"26" },{ "OutcomeMeasurementGroupId":"OG005", "OutcomeMeasurementValue":"10" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Other Pre-specified", "OutcomeMeasureTitle":"Number/Percentage of Subjects Exhibiting CD8+ IFNγ+ Responses", "OutcomeMeasureDescription":"H7N3-specific T cell responses were examined in PBMCs obtained from all the study subjects before vaccination (Day 0), 28 days after the first vaccination (Day 28) and 28 days after revaccination (Day 56). To calculate the frequency of virus-specific T cells we quantified all cells positive for IFNγ after in vitro stimulation with whole H7N3 virion.\n\nIncreases in the antigen-specific CD4+T-cell levels exceeding 3 standard deviations from the levels in the mean of the placebo were considered positive responses.", "OutcomeMeasurePopulationDescription":"Per-Protocol (PP) population that received 2 doses of either vaccine or placebo", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Count of Participants", "OutcomeMeasureUnitOfMeasure":"Participants", "OutcomeMeasureTimeFrame":"Days 0, 28 & 56", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"LAIV H7N3: Dose 1 (Day 0)", "OutcomeGroupDescription":"Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.\n\nName of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.\n\nDose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.\n\nRoute of administration: Intranasal aerosol." },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"Placebo: Dose 1 (Day 0)", "OutcomeGroupDescription":"Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.\n\nDose: 0.5 ml; 0.25 ml/nare\n\nRoute of administration: Intranasal aerosol" },{ "OutcomeGroupId":"OG002", "OutcomeGroupTitle":"LAIV H7N3: Day 28 (Dose 2)", "OutcomeGroupDescription":"Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.\n\nName of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.\n\nDose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.\n\nRoute of administration: Intranasal aerosol." },{ "OutcomeGroupId":"OG003", "OutcomeGroupTitle":"Placebo: Day 28 (Dose 2)", "OutcomeGroupDescription":"Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.\n\nDose: 0.5 ml; 0.25 ml/nare\n\nRoute of administration: Intranasal aerosol" },{ "OutcomeGroupId":"OG004", "OutcomeGroupTitle":"LAIV H7N3: Day 56 (28 Days Past Dose 2)", "OutcomeGroupDescription":"Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.\n\nName of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.\n\nDose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.\n\nRoute of administration: Intranasal aerosol." },{ "OutcomeGroupId":"OG005", "OutcomeGroupTitle":"Placebo: Day 56 (28 Days Past Dose 2)", "OutcomeGroupDescription":"Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.\n\nDose: 0.5 ml; 0.25 ml/nare\n\nRoute of administration: Intranasal aerosol" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"29" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"10" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"29" },{ "OutcomeDenomCountGroupId":"OG003", "OutcomeDenomCountValue":"10" },{ "OutcomeDenomCountGroupId":"OG004", "OutcomeDenomCountValue":"29" },{ "OutcomeDenomCountGroupId":"OG005", "OutcomeDenomCountValue":"10" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeCategoryTitle":"Positive response", "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"5" },{ "OutcomeMeasurementGroupId":"OG003", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG004", "OutcomeMeasurementValue":"5" },{ "OutcomeMeasurementGroupId":"OG005", "OutcomeMeasurementValue":"0" } ] } },{ "OutcomeCategoryTitle":"No response", "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"29" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"10" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"24" },{ "OutcomeMeasurementGroupId":"OG003", "OutcomeMeasurementValue":"10" },{ "OutcomeMeasurementGroupId":"OG004", "OutcomeMeasurementValue":"24" },{ "OutcomeMeasurementGroupId":"OG005", "OutcomeMeasurementValue":"10" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Other Pre-specified", "OutcomeMeasureTitle":"Number/Percentage of Subjects Exhibiting CD8+ IFNγ+ Central Memory T Cell Responses", "OutcomeMeasureDescription":"H7N3-specific T cell responses were examined in PBMCs obtained from all the study subjects before vaccination (Day 0), 28 days after the first vaccination (Day 28) and 28 days after revaccination (Day 56). To calculate the frequency of virus-specific T cells we quantified all cells positive for IFNγ after in vitro stimulation with whole H7N3 virion.\n\nIncreases in the antigen-specific CD4+T-cell levels exceeding 3 standard deviations from the levels in the mean of the placebo were considered positive responses.", "OutcomeMeasurePopulationDescription":"Per-Protocol (PP) population that received 2 doses of either vaccine or placebo", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Count of Participants", "OutcomeMeasureUnitOfMeasure":"Participants", "OutcomeMeasureTimeFrame":"Days 0, 28 & 56", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"LAIV H7N3: Dose 1 (Day 0)", "OutcomeGroupDescription":"Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.\n\nName of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.\n\nDose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.\n\nRoute of administration: Intranasal aerosol." },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"Placebo: Dose 1 (Day 0)", "OutcomeGroupDescription":"Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.\n\nDose: 0.5 ml; 0.25 ml/nare\n\nRoute of administration: Intranasal aerosol" },{ "OutcomeGroupId":"OG002", "OutcomeGroupTitle":"LAIV H7N3: Day 28 (Dose 2)", "OutcomeGroupDescription":"Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.\n\nName of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.\n\nDose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.\n\nRoute of administration: Intranasal aerosol." },{ "OutcomeGroupId":"OG003", "OutcomeGroupTitle":"Placebo: Day 28 (Dose 2)", "OutcomeGroupDescription":"Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.\n\nDose: 0.5 ml; 0.25 ml/nare\n\nRoute of administration: Intranasal aerosol" },{ "OutcomeGroupId":"OG004", "OutcomeGroupTitle":"LAIV H7N3: Day 56 (28 Days Past Dose 2)", "OutcomeGroupDescription":"Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.\n\nName of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.\n\nDose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.\n\nRoute of administration: Intranasal aerosol." },{ "OutcomeGroupId":"OG005", "OutcomeGroupTitle":"Placebo: Day 56 (28 Days Past Dose 2)", "OutcomeGroupDescription":"Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.\n\nDose: 0.5 ml; 0.25 ml/nare\n\nRoute of administration: Intranasal aerosol" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"29" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"10" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"29" },{ "OutcomeDenomCountGroupId":"OG003", "OutcomeDenomCountValue":"10" },{ "OutcomeDenomCountGroupId":"OG004", "OutcomeDenomCountValue":"29" },{ "OutcomeDenomCountGroupId":"OG005", "OutcomeDenomCountValue":"10" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeCategoryTitle":"Positive response", "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"1" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"6" },{ "OutcomeMeasurementGroupId":"OG003", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG004", "OutcomeMeasurementValue":"6" },{ "OutcomeMeasurementGroupId":"OG005", "OutcomeMeasurementValue":"0" } ] } },{ "OutcomeCategoryTitle":"No response", "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"28" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"10" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"23" },{ "OutcomeMeasurementGroupId":"OG003", "OutcomeMeasurementValue":"10" },{ "OutcomeMeasurementGroupId":"OG004", "OutcomeMeasurementValue":"23" },{ "OutcomeMeasurementGroupId":"OG005", "OutcomeMeasurementValue":"10" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Other Pre-specified", "OutcomeMeasureTitle":"Number/Percentage of Subjects Exhibiting CD8+ IFNγ+ Effector Memory T Cell Responses", "OutcomeMeasureDescription":"H7N3-specific T cell responses were examined in PBMCs obtained from all the study subjects before vaccination (Day 0), 28 days after the first vaccination (Day 28) and 28 days after revaccination (Day 56). To calculate the frequency of virus-specific T cells we quantified all cells positive for IFNγ after in vitro stimulation with whole H7N3 virion.\n\nIncreases in the antigen-specific CD4+T-cell levels exceeding 3 standard deviations from the levels in the mean of the placebo were considered positive responses.", "OutcomeMeasurePopulationDescription":"Per-Protocol (PP) population that received 2 doses of either vaccine or placebo", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Count of Participants", "OutcomeMeasureUnitOfMeasure":"Participants", "OutcomeMeasureTimeFrame":"Days 0, 28 & 56", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"LAIV H7N3: Dose 1 (Day 0)", "OutcomeGroupDescription":"Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.\n\nName of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.\n\nDose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.\n\nRoute of administration: Intranasal aerosol." },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"Placebo: Dose 1 (Day 0)", "OutcomeGroupDescription":"Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.\n\nDose: 0.5 ml; 0.25 ml/nare\n\nRoute of administration: Intranasal aerosol" },{ "OutcomeGroupId":"OG002", "OutcomeGroupTitle":"LAIV H7N3: Day 28 (Dose 2)", "OutcomeGroupDescription":"Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.\n\nName of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.\n\nDose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.\n\nRoute of administration: Intranasal aerosol." },{ "OutcomeGroupId":"OG003", "OutcomeGroupTitle":"Placebo: Day 28 (Dose 2)", "OutcomeGroupDescription":"Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.\n\nDose: 0.5 ml; 0.25 ml/nare\n\nRoute of administration: Intranasal aerosol" },{ "OutcomeGroupId":"OG004", "OutcomeGroupTitle":"LAIV H7N3: Day 56 (28 Days Past Dose 2)", "OutcomeGroupDescription":"Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.\n\nName of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.\n\nDose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.\n\nRoute of administration: Intranasal aerosol." },{ "OutcomeGroupId":"OG005", "OutcomeGroupTitle":"Placebo: Day 56 (28 Days Past Dose 2)", "OutcomeGroupDescription":"Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.\n\nDose: 0.5 ml; 0.25 ml/nare\n\nRoute of administration: Intranasal aerosol" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"29" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"10" },{ "OutcomeDenomCountGroupId":"OG002", "OutcomeDenomCountValue":"29" },{ "OutcomeDenomCountGroupId":"OG003", "OutcomeDenomCountValue":"10" },{ "OutcomeDenomCountGroupId":"OG004", "OutcomeDenomCountValue":"29" },{ "OutcomeDenomCountGroupId":"OG005", "OutcomeDenomCountValue":"10" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeCategoryTitle":"Positive response", "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"5" },{ "OutcomeMeasurementGroupId":"OG003", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG004", "OutcomeMeasurementValue":"5" },{ "OutcomeMeasurementGroupId":"OG005", "OutcomeMeasurementValue":"0" } ] } },{ "OutcomeCategoryTitle":"No response", "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"29" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"10" },{ "OutcomeMeasurementGroupId":"OG002", "OutcomeMeasurementValue":"24" },{ "OutcomeMeasurementGroupId":"OG003", "OutcomeMeasurementValue":"10" },{ "OutcomeMeasurementGroupId":"OG004", "OutcomeMeasurementValue":"24" },{ "OutcomeMeasurementGroupId":"OG005", "OutcomeMeasurementValue":"10" } ] } } ] } } ] } } ] } }, "AdverseEventsModule":{ "EventsFrequencyThreshold":"0", "EventsTimeFrame":"Up to 56 days following dosing", "EventsDescription":"For the assessment of safety, subjects were assessed for adverse reactions twice daily (early morning and late afternoon) for 7 days.\n\nAn ear, nose, and throat (ENT) examination was performed on Days 7, 28, 35, and 56.\n\nBlood and urine specimens were also collected on Days 7, 28 (prior to administration of the second dose of study vaccine or placebo), 35 and 56, for testing by routine biochemical and hematological blood tests and by urinalysis by dipstick.", "EventGroupList":{ "EventGroup":[ { "EventGroupId":"EG000", "EventGroupTitle":"LAIV H7N3: Dose 1", "EventGroupDescription":"Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.\n\nName of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.\n\nDose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.\n\nRoute of administration: Intranasal aerosol.", "EventGroupDeathsNumAffected":"0", "EventGroupDeathsNumAtRisk":"30", "EventGroupSeriousNumAffected":"0", "EventGroupSeriousNumAtRisk":"30", "EventGroupOtherNumAffected":"20", "EventGroupOtherNumAtRisk":"30" },{ "EventGroupId":"EG001", "EventGroupTitle":"Placebo: Dose 1", "EventGroupDescription":"Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.\n\nDose: 0.5 ml; 0.25 ml/nare\n\nRoute of administration: Intranasal aerosol", "EventGroupDeathsNumAffected":"0", "EventGroupDeathsNumAtRisk":"10", "EventGroupSeriousNumAffected":"0", "EventGroupSeriousNumAtRisk":"10", "EventGroupOtherNumAffected":"5", "EventGroupOtherNumAtRisk":"10" },{ "EventGroupId":"EG002", "EventGroupTitle":"LAIV H7N3: Dose 2", "EventGroupDescription":"Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.\n\nName of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.\n\nDose: ≥7.5 log EID50/0.5 ml dose; 0.25 ml/nare.\n\nRoute of administration: Intranasal aerosol.", "EventGroupDeathsNumAffected":"0", "EventGroupDeathsNumAtRisk":"30", "EventGroupSeriousNumAffected":"0", "EventGroupSeriousNumAtRisk":"30", "EventGroupOtherNumAffected":"25", "EventGroupOtherNumAtRisk":"30" },{ "EventGroupId":"EG003", "EventGroupTitle":"Placebo: Dose 2", "EventGroupDescription":"Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.\n\nDose: 0.5 ml; 0.25 ml/nare\n\nRoute of administration: Intranasal aerosol", "EventGroupDeathsNumAffected":"0", "EventGroupDeathsNumAtRisk":"10", "EventGroupSeriousNumAffected":"0", "EventGroupSeriousNumAtRisk":"10", "EventGroupOtherNumAffected":"8", "EventGroupOtherNumAtRisk":"10" } ] }, "OtherEventList":{ "OtherEvent":[ { "OtherEventTerm":"Lymphocytosis", "OtherEventOrganSystem":"Blood and lymphatic system disorders", "OtherEventSourceVocabulary":"MedDRA (15.0)", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"10" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG003", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"10" } ] } },{ "OtherEventTerm":"Monocytosis", "OtherEventOrganSystem":"Blood and lymphatic system disorders", "OtherEventSourceVocabulary":"MedDRA (15.0)", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"10" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG003", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"10" } ] } },{ "OtherEventTerm":"Neutropenia", "OtherEventOrganSystem":"Blood and lymphatic system disorders", "OtherEventSourceVocabulary":"MedDRA (15.0)", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"10" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG003", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"10" } ] } },{ "OtherEventTerm":"Blood alkaline phosphatase decreased", "OtherEventOrganSystem":"Investigations", "OtherEventSourceVocabulary":"MedDRA (15.0)", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"10" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG003", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"10" } ] } },{ "OtherEventTerm":"Blood alkaline phosphatase increased", "OtherEventOrganSystem":"Investigations", "OtherEventSourceVocabulary":"MedDRA (15.0)", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"10" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG003", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"10" } ] } },{ "OtherEventTerm":"Blood bicarbonate increased", "OtherEventOrganSystem":"Investigations", "OtherEventSourceVocabulary":"MedDRA (15.0)", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"9", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"3", "OtherEventStatsNumAtRisk":"10" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"5", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG003", "OtherEventStatsNumAffected":"3", "OtherEventStatsNumAtRisk":"10" } ] } },{ "OtherEventTerm":"Blood bilirubin increased", "OtherEventOrganSystem":"Investigations", "OtherEventSourceVocabulary":"MedDRA (15.0)", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"5", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"10" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG003", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"10" } ] } },{ "OtherEventTerm":"Blood calcium increased", "OtherEventOrganSystem":"Investigations", "OtherEventSourceVocabulary":"MedDRA (15.0)", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"10" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"3", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG003", "OtherEventStatsNumEvents":"1", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"10" } ] } },{ "OtherEventTerm":"Blood chloride increased", "OtherEventOrganSystem":"Investigations", "OtherEventSourceVocabulary":"MedDRA (15.0)", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"10" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"3", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG003", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"10" } ] } },{ "OtherEventTerm":"Blood creatinine increased", "OtherEventOrganSystem":"Investigations", "OtherEventSourceVocabulary":"MedDRA (15.0)", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"10" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"6", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG003", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"10" } ] } },{ "OtherEventTerm":"Eosinophil count increased", "OtherEventOrganSystem":"Investigations", "OtherEventSourceVocabulary":"MedDRA (15.0)", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"10" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG003", "OtherEventStatsNumEvents":"0", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"10" } ] } },{ "OtherEventTerm":"Hemoglobin increased", "OtherEventOrganSystem":"Investigations", "OtherEventSourceVocabulary":"MedDRA (15.0)", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"10" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"4", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG003", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"10" } ] } },{ "OtherEventTerm":"Lymphocyte count decreased", "OtherEventOrganSystem":"Investigations", "OtherEventSourceVocabulary":"MedDRA (15.0)", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"10" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG003", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"10" } ] } },{ "OtherEventTerm":"Lymphocyte count increased", "OtherEventOrganSystem":"Investigations", "OtherEventSourceVocabulary":"MedDRA (15.0)", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"6", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"10" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"6", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG003", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"10" } ] } },{ "OtherEventTerm":"Mean cell hemoglobin concentration increased", "OtherEventOrganSystem":"Investigations", "OtherEventSourceVocabulary":"MedDRA (15.0)", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"10" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG003", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"10" } ] } },{ "OtherEventTerm":"Monocyte count increased", "OtherEventOrganSystem":"Investigations", "OtherEventSourceVocabulary":"MedDRA (15.0)", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"5", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"10" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"5", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG003", "OtherEventStatsNumAffected":"3", "OtherEventStatsNumAtRisk":"10" } ] } },{ "OtherEventTerm":"Neutrophil count decreased", "OtherEventOrganSystem":"Investigations", "OtherEventSourceVocabulary":"MedDRA (15.0)", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"4", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"10" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"5", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG003", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"10" } ] } },{ "OtherEventTerm":"White blood cell count increased", "OtherEventOrganSystem":"Investigations", "OtherEventSourceVocabulary":"MedDRA (15.0)", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"10" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG003", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"10" } ] } },{ "OtherEventTerm":"Leukocyturia", "OtherEventOrganSystem":"Renal and urinary disorders", "OtherEventSourceVocabulary":"MedDRA (15.0)", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"10" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG003", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"10" } ] } },{ "OtherEventTerm":"Nasopharyngitis", "OtherEventOrganSystem":"Infections and infestations", "OtherEventSourceVocabulary":"MedDRA (15.0)", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumEvents":"0", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumEvents":"0", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"10" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG003", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"10" } ] } },{ "OtherEventTerm":"Respiratory tract infection viral", "OtherEventOrganSystem":"Infections and infestations", "OtherEventSourceVocabulary":"MedDRA (15.0)", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumEvents":"0", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumEvents":"0", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"10" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG003", "OtherEventStatsNumEvents":"0", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"10" } ] } },{ "OtherEventTerm":"Alanine aminotransferase increased", "OtherEventOrganSystem":"Investigations", "OtherEventSourceVocabulary":"MedDRA (15.0)", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumEvents":"0", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumEvents":"0", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"10" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG003", "OtherEventStatsNumEvents":"0", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"10" } ] } },{ "OtherEventTerm":"Aspartate aminotransferase increased", "OtherEventOrganSystem":"Investigations", "OtherEventSourceVocabulary":"MedDRA (15.0)", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumEvents":"0", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumEvents":"0", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"10" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumEvents":"1", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG003", "OtherEventStatsNumEvents":"1", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"10" } ] } },{ "OtherEventTerm":"Blood glucose increased", "OtherEventOrganSystem":"Investigations", "OtherEventSourceVocabulary":"MedDRA (15.0)", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumEvents":"0", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumEvents":"0", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"10" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"5", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG003", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"10" } ] } },{ "OtherEventTerm":"Hemoglobin decreased", "OtherEventOrganSystem":"Investigations", "OtherEventSourceVocabulary":"MedDRA (15.0)", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumEvents":"0", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumEvents":"0", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"10" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG003", "OtherEventStatsNumEvents":"0", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"10" } ] } },{ "OtherEventTerm":"Platelet count increased", "OtherEventOrganSystem":"Investigations", "OtherEventSourceVocabulary":"MedDRA (15.0)", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumEvents":"0", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumEvents":"0", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"10" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG003", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"10" } ] } },{ "OtherEventTerm":"Total protein decreased", "OtherEventOrganSystem":"Investigations", "OtherEventSourceVocabulary":"MedDRA (15.0)", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"10" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG003", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"10" } ] } },{ "OtherEventTerm":"Red blood cell increased", "OtherEventOrganSystem":"Investigations", "OtherEventSourceVocabulary":"MedDRA (15.0)", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"10" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG003", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"10" } ] } },{ "OtherEventTerm":"Red blood cell sedimentation rate increased", "OtherEventOrganSystem":"Investigations", "OtherEventSourceVocabulary":"MedDRA (15.0)", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"10" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG003", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"10" } ] } },{ "OtherEventTerm":"Urine leukocyte esterase positive", "OtherEventOrganSystem":"Investigations", "OtherEventSourceVocabulary":"MedDRA (15.0)", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"10" },{ "OtherEventStatsGroupId":"EG002", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"30" },{ "OtherEventStatsGroupId":"EG003", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"10" } ] } } ] } }, "MoreInfoModule":{ "LimitationsAndCaveats":{}, "CertainAgreement":{ "AgreementPISponsorEmployee":"No", "AgreementRestrictiveAgreement":"No" }, "PointOfContact":{ "PointOfContactTitle":"Jorge Flores", "PointOfContactOrganization":"PATH", "PointOfContactEMail":"jeflores@path.org", "PointOfContactPhone":"(202) 822-0033" } } }, "DerivedSection":{ "MiscInfoModule":{ "VersionHolder":"April 22, 2020" }, "ConditionBrowseModule":{ "ConditionMeshList":{ "ConditionMesh":[ { "ConditionMeshId":"D000007251", "ConditionMeshTerm":"Influenza, Human" },{ "ConditionMeshId":"D000005585", "ConditionMeshTerm":"Influenza in Birds" } ] }, "ConditionAncestorList":{ "ConditionAncestor":[ { "ConditionAncestorId":"D000009976", "ConditionAncestorTerm":"Orthomyxoviridae Infections" },{ "ConditionAncestorId":"D000012327", "ConditionAncestorTerm":"RNA Virus Infections" },{ "ConditionAncestorId":"D000014777", "ConditionAncestorTerm":"Virus Diseases" },{ "ConditionAncestorId":"D000012141", "ConditionAncestorTerm":"Respiratory Tract Infections" },{ "ConditionAncestorId":"D000012140", "ConditionAncestorTerm":"Respiratory Tract Diseases" } ] }, "ConditionBrowseLeafList":{ "ConditionBrowseLeaf":[ { "ConditionBrowseLeafId":"M8878", "ConditionBrowseLeafName":"Influenza, Human", "ConditionBrowseLeafAsFound":"Influenza", "ConditionBrowseLeafRelevance":"high" },{ "ConditionBrowseLeafId":"M7290", "ConditionBrowseLeafName":"Influenza in Birds", "ConditionBrowseLeafAsFound":"Avian Influenza", "ConditionBrowseLeafRelevance":"high" },{ "ConditionBrowseLeafId":"M8866", "ConditionBrowseLeafName":"Infection", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M4951", "ConditionBrowseLeafName":"Communicable Diseases", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M11485", "ConditionBrowseLeafName":"Orthomyxoviridae Infections", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M16105", "ConditionBrowseLeafName":"Virus Diseases", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M13732", "ConditionBrowseLeafName":"RNA Virus Infections", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M13561", "ConditionBrowseLeafName":"Respiratory Tract Infections", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M13560", "ConditionBrowseLeafName":"Respiratory Tract Diseases", "ConditionBrowseLeafRelevance":"low" } ] }, "ConditionBrowseBranchList":{ "ConditionBrowseBranch":[ { "ConditionBrowseBranchAbbrev":"BC02", "ConditionBrowseBranchName":"Viral Diseases" },{ "ConditionBrowseBranchAbbrev":"BC08", "ConditionBrowseBranchName":"Respiratory Tract (Lung and Bronchial) Diseases" },{ "ConditionBrowseBranchAbbrev":"All", "ConditionBrowseBranchName":"All Conditions" },{ "ConditionBrowseBranchAbbrev":"BC01", "ConditionBrowseBranchName":"Bacterial and Fungal Diseases" } ] } } } } } }